A new kind of liquid biopsy
The molecular signal has always been there.
Now we can read it.
allumbra combines a quantum sensing technology with AI to extract rich molecular information from blood to create powerful tests that detect cancer sooner.
Our Team
The people behind the signal.
allumbra was founded by scientists united by a single conviction: cancer leaves a molecular trace long before a tumor is visible. We built the instrument to read it.
Maria Navas-Moreno, PhD
CEO & CO-FOUNDER
Randy Carney, PhD
CSO & CO-FOUNDER
Our Science
Peer-reviewed publications
More publications ➔
Fused Raman spectroscopic analysis of blood and saliva delivers high accuracy for head and neck cancer diagnostics
Scientific Reports, 2022
Label-free Raman spectroscopy of extracellular vesicles for early-stage liquid biopsy cancer detection
AACR Annual Meeting 2024
Towards a generalized machine learning model for Raman spectroscopy-based liquid biopsy in cancer screening using self-supervised learning
Conference on Liquid Biopsy 2024
For investors & partners
Quarterly updates.
Receive updates on our science, our team and our business progress.
Four emails a year. Unsubscribe anytime.
Contact
Get in touch.
We work with clinical sites, research collaborators, and strategic partners. Tell us where you are and we’ll route you to the right person.
Press
Partnerships
General
Send us a message.